Table 3 Summary of adverse events
eGFR (mL/min/1.73 m2) | ||||
|---|---|---|---|---|
≧90 | ≧60 to <90 | ≧30 to <60 | P value | |
Number of subjects | 99 | 525 | 228 | |
All adverse events | 82 (82.8%) | 462 (88.0%) | 198 (86.8%) | 0.3609* |
gastrointestinal symptoms–relate adverse events | 33 (33.3%) | 192 (36.6%) | 88 (38.6%) | 0.6631* |
Abdominal pain upper | 4 (4.0%) | 31 (5.9%) | 7 (3.1%) | NT |
Constipation | 4 (4.0%) | 37 (7.0%) | 19 (8.3%) | NT |
Diarrhoea | 4 (4.0%) | 17 (3.2%) | 12 (5.3%) | NT |
Stomach discomfort | 11 (11.1%) | 44 (8.4%) | 14 (6.1%) | NT |
Urinary- and kidney function-related adverse events | 2 (2.0%) | 11 (2.1%) | 7 (3.1%) | 0.6295* |
Osteonecrosis of the jaw | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | NT |
Atypical femoral fractures | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | NT |